Persistent Systems Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/pi59yaw0blbehyuwn4709da3.pdf

Key Takeaways


Margins & Profitability

Kalra: "We could have, it doesn't take too much to cut costs, it takes a lot to provide growth."

Demand Environment & Deal Wins

Kalra: "If you look at our deal wins for the Q1, that was a tad bit lower than the earlier quarters and we very clearly said some of the deal wins had moved or shifted over to the next quarter. And they have come in along with a very healthy Q2 as well."

Vertical & Geographic Performance

Vertical / GeographyTrendCommentary
Hi-tech▲ StrengthDriven by engineering core, PE carveout deals, and GenAI tooling; management says Persistent is "much ahead of competition" and expects it to remain a growth engine.
Healthcare▲ GainingMost traction in the Payer segment (large insurers), with good conversion in Scientific Instruments and Medical Devices. Winning as a "disruptor" against tier-1 Indian and US competitors.
BFSI▬ FlatFlat QoQ on a base of strong prior quarters; no further caution from large clients beyond what was already known. Persistent is being brought into renewals and rebids where clients are "fatigued with tier-1 providers."
North America▬ In lineGrew in line with company average.
Europe▬ Nearly flatNearly flat for the quarter.
Rest of World▲ SurgeGrew 41.8% QoQ, albeit on a low base.

People & Talent


AI & GenAI

Kalra: "If we can disrupt ourselves, the market for us is huge. So, we are not worried about disrupting ourselves, we are worried about providing the right value to our customers and bringing them the latest and greatest."

Competitive Positioning

Kalra: "I'm proud to say that a small team Persistent, a billion-dollar company, is winning against $10 billion, $20 billion, $30 billion companies, and that's where we are gaining market share in newer customers and even in some of our existing customers."

Guidance & Commitments

CommitmentSpecificsTimeline
EBIT margin improvementExpand by 150–200 bpsOver the next 2–3 years
EBITDA margin expansionExpand by 2–3%Over the next 2–3 years
OCF to EBITDAAchieve 0.7 for the full yearFY24
UtilizationAspirational target of 83–84%No date (current: 80.6%)
M&AActive on the M&A front; will report progressOver the next several quarters
Dividend policyUnchanged for now; will revisit if no further acquisitions over timeConditional on M&A activity
Forward guidanceWill no longer provide quarterly growth or margin guidanceEffective immediately

Key Metrics

MetricQ2 FY24
Revenue (USD)$291.71 million, +3.1% QoQ and +14.1% YoY
Revenue (INR)₹2,411.67 crore, +3.9% QoQ and +17.7% YoY
EBIT margin13.7%, declined 120 bps QoQ; wage hike impact of 2.7% partially offset by utilization, currency, and lower visa costs
EBITDA margin16.8%, vs 18.2% in Q1; one-off expenses offset by one-off credit from earnout liability reduction
Profit after tax₹263.27 crore, 10.9% of revenue; EPS of ₹35 vs ₹30.5 in Q1
H1 revenue (USD)$574.61 million, +15.6% YoY
H1 revenue (INR)₹4,732.85 crore, +20.5% YoY
H1 EBIT margin14.3%, vs 14.5% in H1 FY23; absolute EBIT grew 19.4% YoY
Total contract value (TCV)$479.3 million, with new order book TCV of $313.1 million
Annual contract value (ACV)$315.9 million (component of TCV), with new ACV of $184.2 million
Healthcare & Life Sciences growth7% QoQ
Hi-Tech & Emerging Verticals growth3.8% QoQ
BFSI growthFlat QoQ
North America revenue growth3.1% QoQ in USD terms
Europe revenue growth0.3% QoQ
India revenue growth1.3% QoQ
Rest of World revenue growth41.8% QoQ on a low revenue base
Total headcount22,842, decline of 282 FTEs from Q1
Blended utilization80.6%, up from 78.3% in Q1
Trailing 12-month attrition13.5%, down from 15.5% in Q1
Customers in >$1 million bucket175, increase of 8 over Q1
Top 5 customer revenue growth4.5% QoQ
Top 10 customer revenue growth2.8% QoQ
Top 50 customer revenue growth3.7% QoQ, better than overall company growth
DSO66 days, improved from 67 days in Q1
Cash and investments₹1,568.3 crore as of September 30, vs ₹1,409.3 crore at end of June
Cash conversion (OCF to EBITDA)119% for Q2; H1 at 0.55 vs 0.54 in H1 FY23
Forward contracts outstanding$240 million at an average rate of 83.92 per dollar
ROCE30.2%, vs 30.4% in Q1
Effective tax rate26%, vs 25.5% in Q1
Freshers onboarded277 in Q2
EBIT margin improvement target150 to 200 bps over the next two to three years
Aspirational utilization range83–84%; every 1% utilization improvement impacts PAT by 30 bps
ACV revenue conversion leakage10–15% currently, vs less than 10% earlier; in rare cases a little more